Premium
Parenteral diphosphonates for treating malignant hypercalcemia
Author(s) -
Jung A.,
Van Ouwenaller C.,
Chantraine A.,
Courvoisier B.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19811015)48:8<1922::aid-cncr2820480833>3.0.co;2-2
Subject(s) - diphosphonates , medicine , bone resorption , resorption
Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy‐diphosphonate) and Cl 2 MDP (disodium clodronate, or dichloromethylene‐diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia. All patients responded well to the drugs after a delay period of two to seven days. The tolerance of the drugs was excellent. EHDP, and especially Cl 2 MDP, are promising agents for treating hypercalcemia and inhibiting bone resorption in malignant disorders.